{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:39:17Z","timestamp":1767591557827,"version":"3.48.0"},"reference-count":19,"publisher":"National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)","issue":"3","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp. oncol."],"abstract":"<jats:p>Background. Resistance of the advanced breast cancer (aBC) to hormone therapy and chemotherapy due to hyperactivated PI3K-pathway caused by mutations in the PIK3CA gene is a major treatment problem. Combining pegylated liposomal doxorubicin (PLD) with mild magnetothermy (MT) and letrozole could improve the efficacy of treatment. The aim was to assess the effect of combined treatment with PLD, MT, and letrozole on the survival of patients with luminal B postmenopausal aBC with mutations in the PIK3CA gene. Material and Methods. The aBC postmenopausal patients who progressed on a cyclin-dependent kinase 4\/6 inhibitor (CDK4\/6i) and an aromatase inhibitor (AI) or neoadjuvant chemotherapy (ACT) were included in the study. Group 1 included 20 patients, treated with PLD + MT every 28 days (4 courses) and letrozole (daily per os, 4 months). Group 2 included 20 patients, who received the same treatment without letrozole. By PIK3\u0421\u0410 status, each group included 10 patients with a mutant PIK3\u0421\u0410 and 10 patients with a wild-type gene. Results. Application of PLD + MT in combination with letrozole demonstrated improved progression-free survival (PFS) compared to PLD + MT alone. In group 1, the median PFS was 10.6 months (95% CI, 7.4\u201411.9 months) compared to a median PFS of 8.9 months (95% CI, 6.1\u20149.7 months) in group 2 (p = 0.005). In the sensitivity analyses, PFS of patients with wild-type PIK3CA in the first cohort was 10.1 months (95% CI, 8.7\u201411.1 months) compared to 8.4 months (95% CI, 7.0\u201410.4 months) in groups 1 and 2 respectively (p = 0.004), by 1:1 greedy nearest neighbor matching. Conclusion. PLD with local MH in combination with letrozole was more effective irrespective of the PIK3CA gene status in postmenopausal aBC patients.<\/jats:p>","DOI":"10.15407\/exp-oncology.2025.03.356","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T10:19:05Z","timestamp":1767521945000},"page":"356-360","source":"Crossref","is-referenced-by-count":0,"title":["LETROZOLE IMPROVES PROGRESSION-FREE SURVIVAL OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH PEGYLATED LIPOSOMAL DOXORUBICIN AND MAGNETOTHERMY"],"prefix":"10.15407","volume":"47","author":[{"given":"A.","family":"Loboda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Movchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Smolanka (Sr)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu.","family":"Dumanskyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lyashenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Ivankova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Dosenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"32237","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Subhan M, Parveen f, Shah h, et al. Recent advances with precision medicine treatment for breast cancer including triple-negative sub-type. Cancers (Basel). 2023;15(8):2204. https:\/\/doi.org\/10.3390\/cancers15082204","DOI":"10.3390\/cancers15082204"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Emran T, Shahriar A, Mahmud A, et al. Multidrug resistance in cancer: Understanding molecular mecha- nisms, immunoprevention and therapeutic approaches. Front Oncol. 2022;12:891652. https:\/\/doi.org\/10.3389\/ fonc.2022.891652","DOI":"10.3389\/fonc.2022.891652"},{"key":"ref2","unstructured":"Globus O, Greenhouse I, Sella T, et al. The neoadjuvant systemic treatment of early breast cancer: a narrative review."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ann Breast Surg. 2023;7:39. https:\/\/doi.org\/10.21037\/abs-21-109","DOI":"10.21037\/abs-21-109"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Bertucci A, Bertucci f, Gon\u00e7alves A. Phosphoinositide 3-kinase (PI3K) inhibitors and breast cancer: An overview of current achievements. Cancers (Basel). 2023;15(5):1416. https:\/\/doi.org\/10.3390\/cancers15051416","DOI":"10.3390\/cancers15051416"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ben Rekaya M, Sassi f, Saied E, Bel haj Kacem L. PIK3CA mutations in breast cancer: A Tunisian series. PLoS One. 2023;18(5):e0285413. https:\/\/doi.org\/10.1371\/journal.pone.0285413","DOI":"10.1371\/journal.pone.0285413"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Zhou d, Ouyang Q, Liu L, et al. Chemotherapy modulates endocrine therapy-related resistance mutations in meta- static breast cancer. Transl Oncol. 2019;12(5):764-774. https:\/\/doi.org\/10.1016\/j.tranon.2019.02.014","DOI":"10.1016\/j.tranon.2019.02.014"},{"key":"ref7","unstructured":"Movchan OV, Smolanka II, Lyashenko AO, et al. Pegylated liposomal doxorubicin for PIK3CA \"wild\", hR+, hER2-, chemoresistant advanced breast cancer. Onkologia Radioterapia. 2025;19(5):1-5."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Regenold M, Kaneko K, Wang X, et al. Triggered release from thermosensitive liposomes improves tumor targeting of vinorelbine. J Control Release. 2023;354:19-33. https:\/\/doi.org\/10.1016\/j.jconrel.2022.12.010","DOI":"10.1016\/j.jconrel.2022.12.010"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Orel VE, Shevchenko Ad, Bogatyreva GP, et al. Magnetic characteristics and anticancer activity of a nanocom- plex consisting of detonation nanodiamond and doxorubicin. J Superhard Mater. 2012;34(3):179-185. https:\/\/doi. org\/10.3103\/S1063457612030057","DOI":"10.3103\/S1063457612030057"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Malik J, Ahmed S, Jan B, et al. drugs repurposed: An advanced step towards the treatment of breast cancer and challenges. Biomed Pharmacother. 2022;145:112375. https:\/\/doi.org\/10.1016\/j.biopha.2021.112375","DOI":"10.1016\/j.biopha.2021.112375"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Teomete M, Cabuk d, Korkmaz T, et al. Recommendations for cyclin-dependent kinase 4\/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review). Oncol Lett. 2024;27:145. https:\/\/doi.org\/10.3892\/ ol.2024.14278","DOI":"10.3892\/ol.2024.14278"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Cerma K, Piacentini f, Moscetti L, et al. Targeting PI3K\/AKT\/mTOR pathway in breast cancer: from biology to clinical challenges. Biomedicines. 2023;11(1):109. https:\/\/doi.org \/10.3390\/biomedicines11010109","DOI":"10.3390\/biomedicines11010109"},{"key":"ref13","unstructured":"Sirico M, d'Angelo A, Gianni C, et al. Current state and future challenges for pi3k inhibitors in cancer therapy."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Cancers (Basel). 2023;15(3):703. https:\/\/doi.org\/10.3390\/cancers15030703","DOI":"10.3390\/cancers15030703"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Loboda A, Smolanka I Sr, Orel VE, et al. Efficacy of combination neoadjuvant chemotherapy and regional inductive moderate hyperthermia in the treatment of patients with locally advanced breast cancer. Technol Cancer Res Treat. 2020;19:1533033820963599. https:\/\/doi.org\/10.1177\/1533033820963599","DOI":"10.1177\/1533033820963599"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Li y, Qi L, Wang y, et al. A multicenter randomized trials to compare the bioequivalence and safety of a generic doxo- rubicin hydrochloride liposome injection with Caelyx \u00ae in advanced breast cancer. Front Oncol. 2022;12:1070001. https:\/\/doi.org\/10.3389\/fonc.2022.1070001","DOI":"10.3389\/fonc.2022.1070001"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Tang L, he M, Wu J et al. et al. Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLd) or doxorubicin. J Clin Oncol. 2023;41:550-550. https:\/\/doi.org\/10.1200\/ JCO.2023.41.16_suppl.550","DOI":"10.1200\/JCO.2023.41.16_suppl.550"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Klimanov Myu, Syvak LA, Orel VE, et al. Efficacy of combined regional inductive moderate hyperthermia and chemotherapy in patients with multiple liver metastases from breast cancer. Technol Cancer Res Treat. 2018;17:1-7. https:\/\/doi.org\/10.1177\/1533033818806003","DOI":"10.1177\/1533033818806003"}],"container-title":["Experimental Oncology"],"original-title":[],"link":[{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/542\/439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/542\/439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:35:05Z","timestamp":1767591305000},"score":1,"resource":{"primary":{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/view\/542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,30]]}},"URL":"https:\/\/doi.org\/10.15407\/exp-oncology.2025.03.356","relation":{},"ISSN":["2312-8852","1812-9269"],"issn-type":[{"type":"electronic","value":"2312-8852"},{"type":"print","value":"1812-9269"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}